Literature DB >> 30309468

Provider Specialty, Anticoagulation, and Stroke Risk in Patients With Atrial Fibrillation and Cancer.

Wesley T O'Neal1, J'Neka S Claxton2, Pratik B Sandesara3, Richard F MacLehose4, Lin Y Chen5, Lindsay G S Bengtson6, Alanna M Chamberlain7, Faye L Norby4, Pamela L Lutsey4, Alvaro Alonso2.   

Abstract

BACKGROUND: It is unknown whether early cardiology involvement shortly after atrial fibrillation (AF) diagnosis is associated with favorable outcomes in AF patients who have cancer.
OBJECTIVES: The purpose of this study was to examine the relationship between early cardiology involvement after AF diagnosis in patients with history of cancer.
METHODS: This study examined associations of early cardiology involvement with oral anticoagulation use, stroke, and bleeding among nonvalvular AF patients (n = 388,045; mean age 68 ± 15 years; 59% male) with a history of cancer (past or active) from the MarketScan database (2009 to 2014). International Classification of Disease-9th Revision-Clinical Modification codes in any position were used to identify cancer diagnosis prior to AF diagnosis. Provider specialty and filled anticoagulant prescriptions 3 months prior to and 6 months after AF diagnosis were obtained. Poisson regression models were used to compute the probability of an oral anticoagulant prescription fill, and Cox regression was used to estimate the risks of stroke and major bleeding.
RESULTS: A total of 64,016 (17%) AF patients had a history of cancer. Cardiology involvement was less likely to occur among patients with a history of cancer than those without (relative risk [RR]: 0.92 [95% confidence interval (CI): 0.91 to 0.93]). Patients with history of cancer were less likely to fill prescriptions for anticoagulants (RR: 0.89 [95% CI: 0.88 to 0.90]) than those without cancer, and similar results were observed across cancer types. Patients with cancer were more likely to fill prescriptions for anticoagulants (RR: 1.48 [95% CI: 1.45 to 1.52]) if seen by a cardiologist. A reduced risk of stroke (hazard ratio: 0.89 [95% CI: 0.81 to 0.99]) was observed among all cancer patients who were seen by a cardiology provider, without an increased risk of bleeding (hazard ratio: 1.04 [95% CI: 0.95 to 1.13]). Similar results were observed when the analysis was stratified by active versus remote history of cancer.
CONCLUSIONS: Although AF patients with cancer were less likely to see a cardiologist, or fill anticoagulant prescriptions, cardiology involvement was associated with increased anticoagulant prescription fills and favorable AF-related outcomes in AF patients with cancer.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anticoagulation; atrial fibrillation; provider

Mesh:

Substances:

Year:  2018        PMID: 30309468      PMCID: PMC6512871          DOI: 10.1016/j.jacc.2018.07.077

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  25 in total

1.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

2.  Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients.

Authors:  Yu-feng Hu; Chia-jen Liu; Peter Mu-hsin Chang; Hsuan-ming Tsao; Yenn-jiang Lin; Shih-lin Chang; Li-wei Lo; Ta-chuan Tuan; Cheng-hung Li; Tze-fan Chao; Fa-po Chung; Jo-nan Liao; Tzeng-Ji Chen; Shih-ann Chen
Journal:  Int J Cardiol       Date:  2012-09-16       Impact factor: 4.164

3.  Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry.

Authors:  Chiara Melloni; Peter Shrader; Joseph Carver; Jonathan P Piccini; Laine Thomas; Gregg C Fonarow; Jack Ansell; Bernard Gersh; Alan S Go; Elaine Hylek; Irving M Herling; Kenneth W Mahaffey; Anthony F Yu; Eric D Peterson; Peter R Kowey
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2017-07-01

4.  Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study.

Authors:  Mintu P Turakhia; Donald D Hoang; Xiangyan Xu; Susan Frayne; Susan Schmitt; Felix Yang; Ciaran S Phibbs; Claire T Than; Paul J Wang; Paul A Heidenreich
Journal:  Am Heart J       Date:  2012-11-20       Impact factor: 4.749

5.  Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data.

Authors:  Renu K Garg; Nicole L Glazer; Kerri L Wiggins; Katherine M Newton; Evan L Thacker; Nicholas L Smith; David S Siscovick; Bruce M Psaty; Susan R Heckbert
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-12-23       Impact factor: 2.890

6.  Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study).

Authors:  Wesley T O'Neal; Susan G Lakoski; Waqas Qureshi; Suzanne E Judd; George Howard; Virginia J Howard; Mary Cushman; Elsayed Z Soliman
Journal:  Am J Cardiol       Date:  2015-01-31       Impact factor: 2.778

7.  A comparison of 12 algorithms for matching on the propensity score.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2013-10-07       Impact factor: 2.373

8.  Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation.

Authors:  Wesley T O'Neal; Pratik B Sandesara; J'Neka S Claxton; Richard F MacLehose; Lin Y Chen; Lindsay G S Bengtson; Alanna M Chamberlain; Faye L Norby; Pamela L Lutsey; Alvaro Alonso
Journal:  J Am Heart Assoc       Date:  2018-03-10       Impact factor: 5.501

9.  Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study.

Authors:  Steven A Lubitz; Xiaoyan Yin; Michiel Rienstra; Renate B Schnabel; Allan J Walkey; Jared W Magnani; Faisal Rahman; David D McManus; Thomas M Tadros; Daniel Levy; Ramachandran S Vasan; Martin G Larson; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2015-03-13       Impact factor: 29.690

10.  Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry.

Authors:  Emil L Fosbol; DaJuanicia N Holmes; Jonathan P Piccini; Laine Thomas; James A Reiffel; Roger M Mills; Peter Kowey; Kenneth Mahaffey; Bernard J Gersh; Eric D Peterson
Journal:  J Am Heart Assoc       Date:  2013-07-18       Impact factor: 5.501

View more
  11 in total

Review 1.  Vascular Toxicity in Patients with Cancer: Is There a Recipe to Clarify Treatment? CME.

Authors:  Jose Alvarez-Cardona; Joshua Mitchell; Daniel Lenihan
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 2.  Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week.

Authors:  Ramya C Mosarla; Muthiah Vaduganathan; Arman Qamar; Javid Moslehi; Gregory Piazza; Robert P Giugliano
Journal:  J Am Coll Cardiol       Date:  2019-03-26       Impact factor: 24.094

3.  DOACs for stroke prevention in patients with AF and cancer.

Authors:  Dipal Mehta; Daniel M Jones; Avirup Guha; Peter K MacCallum; Amitava Banerjee; Charlotte Manisty; Thomas Crake; Mark Westwood; Arjun K Ghosh
Journal:  Br J Cardiol       Date:  2020-12-02

Review 4.  Atrial Fibrillation and Cancer Patients: Mechanisms and Management.

Authors:  David L Madnick; Michael G Fradley
Journal:  Curr Cardiol Rep       Date:  2022-08-17       Impact factor: 3.955

5.  Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter.

Authors:  Michael G Fradley; Kerry Ellenberg; Mohammed Alomar; Justin Swanson; Anant Kharod; Anh Thy H Nguyen; Sara Khodor; Shreya Mishra; Linh M Duong; Nirav Shah; Merna Armanious; Isaac B Rhea; Matthew B Schabath; Kevin E Kip
Journal:  JACC CardioOncol       Date:  2020-12-15

6.  Cardiology Involvement in Patients with Breast Cancer Treated with Trastuzumab.

Authors:  Biniyam G Demissei; Srinath Adusumalli; Rebecca A Hubbard; Srinivas Denduluri; Vivek Narayan; Amy S Clark; Payal Shah; Hayley Knollman; Kelly D Getz; Richard Aplenc; Joseph R Carver; Bonnie Ky
Journal:  JACC CardioOncol       Date:  2020-06-16

7.  Atrial fibrillation in older adults with cancer.

Authors:  Manish Kumar; Nerea Lopetegui-Lia; Christina Al Malouf; Mansour Almnajam; Patrick P Coll; Agnes S Kim
Journal:  J Geriatr Cardiol       Date:  2022-01-28       Impact factor: 3.327

Review 8.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

9.  Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study.

Authors:  Victor Chien-Chia Wu; Chun-Li Wang; Yu-Tung Huang; Wen-Ching Lan; Michael Wu; Chang-Fu Kuo; Shao-Wei Chen; Pao-Hsien Chu; Ming-Shien Wen; Chi-Ching Kuo; Shang-Hung Chang
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

10.  Low serum albumin levels predict poor outcome in patients with acute ischaemic stroke or transient ischaemic attack.

Authors:  Hongyu Zhou; Anxin Wang; Xia Meng; Jinxi Lin; Yong Jiang; Jing Jing; Yingting Zuo; Yilong Wang; Xingquan Zhao; Hao Li; Yongjun Wang
Journal:  Stroke Vasc Neurol       Date:  2021-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.